| Literature DB >> 30134524 |
Marziyeh Ajdary1, Mohammad Amin Moosavi2, Marveh Rahmati3, Mojtaba Falahati4, Mohammad Mahboubi5, Ali Mandegary6,7, Saranaz Jangjoo8, Reza Mohammadinejad9, Rajender S Varma10.
Abstract
Nanoparticles (NPs) are currently used in diagnosis and treatment of many human diseases, including autoimmune diseases and cancer. However, cytotoxic effects of NPs on normal cells and living organs is a severe limiting factor that hinders their use in clinic. In addition, diversity of NPs and their physico-chemical properties, including particle size, shape, surface area, dispersity and protein corona effects are considered as key factors that have a crucial impact on their safe or toxicological behaviors. Current studies on toxic effects of NPs are aimed to identify the targets and mechanisms of their side effects, with a focus on elucidating the patterns of NP transport, accumulation, degradation, and elimination, in both in vitro and in vitro models. NPs can enter the body through inhalation, skin and digestive routes. Consequently, there is a need for reliable information about effects of NPs on various organs in order to reveal their efficacy and impact on health. This review covers the existing knowledge base on the subject that hopefully prepares us better to address these challenges.Entities:
Keywords: nanoparticles; organ-specific effects; toxicological effects
Year: 2018 PMID: 30134524 PMCID: PMC6164883 DOI: 10.3390/nano8090634
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.076
Figure 1Nanotechnology transformative innovations in medicine, agriculture, industry, environment, and basic biological sciences.
Figure 2The main routes of nanoparticles (NP) entry into the cells and their subsequent intracellular mechanism(s) [24].
Figure 3The most common mechanisms underlying NP cytotoxicity.
Figure 4Schematic illustrating single-walled carbon nanotubes (SWCNTs)-induced interactions with tau protein structure, resulting in pronounced conformational changes and corresponding denaturation compared to multi-walled carbon nanotubes (MWCNT) [40].
Figure 5Toxic effects of diverse types of nanoparticles on various organs.
Toxic effects of nanoparticles on different organs/tissues.
| Target | NP | Concentration, (Size), (Time), Route of Administration | Major Outcomes | Cell | In Vitro Effect |
|---|---|---|---|---|---|
| Brain | AuNP | 0.8–50 μg/mL, (3, 5, 7, 10, 30 and 60 nm), (24 h) | Only the smallest NP tested (3 nm) induced mild signs of cellular toxicity [ | rBMEC (primary rat brain microvessel endothelial cells) | Non-toxic even at highest concentrations in 24 h [ |
| 50 μg/mL (6–120 h) | - | Zebrafish cembryos | Time- and dose-dependent correlating increases in permeability and cytotoxicity of cells [ | ||
| AgNP | 6.25–50 μg/mL, (25, 40 or 80 nm in size), (24 h) | Time- and dose-dependent increase in pro-inflammatory cytokine release and related rises in permeability and cytotoxicity of cells [ | rBMEC (primary rat brain microvessel endothelial cells) | Time- and dose-dependent increase in pro-inflammatory cytokine release and correlating increases in permeability and cytotoxicity of cells [ | |
| Cu | 30–50 mg/Kg | increasing toxicity on neuromuscular system and increase NPs penetration of the blood-brain barrier [ | - | - | |
| Al | 30–50 mg/Kg | increasing toxicity on neuromuscular system and increase NPs penetration of the blood-brain barrier [ | - | - | |
| CdSe | 1, 10, 20 nm, (24 h) | - | Primary rat hippocampal neuron cells in culture | Decrease of cells viability [ | |
| Superparamagnetic iron-oxide nanoparticles (SPION) | 208 or 1042 μg/mL of: Ferumoxtran-10; Ferumoxytol (20–50 nm); Ferumoxide (60–185 nm) (3 months) | Increasing uptake NPs into the CNS parenchyma [ | Murine neural stem cells (NSCs) | Depleted intracellular glutathione levels, altered activities of SOD and GPx, hyperpolarization of the mitochondrial membrane, dissipated cell-membrane potential and increased DNA damage [ | |
| TiO2 | 30–45 nm, (2–72 h) | leakage of lactate dehydrogenase (LDH) [ | Neuro-2A | permeability of NPs in plasma membrane, increasing apoptosis [ | |
| ZnO | |||||
| Fe2O3 | |||||
| Al2O3 | |||||
| CrO3 | |||||
| CNT | PEG-SWCNTs at concentrations of 0.5, 2.1 and 1 mg/mL | Accumulation in the hippocampus which induces oxidative stress [ | PC12 cells | Decreased mitochondrial membrane potential (MMP), induced ROS and increased the level of lipid peroxide and decreased the activities of superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), catalase (CAT) and glutathione (GSH) [ | |
| QD | 0.68 mg containing 50 nmol Cd (13.5 nm in size), (6 h) Intraperitoneal | Moderately high quantities of Cd ions was observed in brain tissue but no signs of inflammation or parenchymal damage were detected [ | Neuron like PC12 cells | Cell death, axonal degeneration [ | |
| Lung | AgNP | 515 g/m3, (6 h/day, 5 days/week for 13 weeks), inhalation | Dose- and time-dependent increase in blood Ag nanoparticle concentration was observed along with correlating increases in alveolar inflammation and small granulomatous lesions [ | - | - |
| Cu | 0.1–3300 µg/mL, (3 and 24 h) | - | Human pulmonary cell line (lung adenocarcinoma epithelial cell line (A549)) | Mitochondria-dependent cellular apoptosis associated with ROS [ | |
| Zn | |||||
| CO | |||||
| Sb | |||||
| Ag | |||||
| Ni | |||||
| Fe | |||||
| CuO | 0–40 μg/cm2 | - | Human lung epithelial cells (A549) | Mitochondria-dependent cellular apoptosis associated with DNA damage [ | |
| SPION | 200–1000 μg/mL, (24 h) | Increased cytokines, inflammation, TNF-α [ | Human lung epithelial cells (A549) | Activation of JNK, stimulation of tumor necrosis factor-alpha (TNFα), reduction of NF-kB, increased ROS [ | |
| SWCNT | 10–100 μg/mL (24 h, 48 h and 72 h) | Dose- and time-dependent decline in cell viability: up to 50% decrease at maximum dosage after 72 h. Oxidative stress was exhibited as a mechanism of cytotoxicity [ | Human lung epithelial cells (A549) | low acute toxicity was confirmed with the in vivo model by dispersion of SWCNTs in serum [ | |
| QD | 12.5 µg, (7 days) | Increased levels of LDH and albumin [ | Human lung adenocarcinoma cells | Mitochondria-dependent cellular apoptosis associated with decrease of cells viability [ | |
| Heart | AgNPs | 100, 1000 and 10,000 ppm, (period of 13 weeks) | increasing cardiocyte deformity, congestion and inflammation [ | Catla heart cell line (SICH) | Increased lipid peroxidation (LPO) level and decreased level of GSH, SOD and CAT [ |
| Iron oxide NPs | 100, 200, 300 and 500 μg/mL, (period of 2 weeks) | Showed that baseline maximal oxidative capacities were proteins in the heart [ | Cardiac microvascular endothelial cells | Induced a concentration- and time-dependent cytotoxicity with decrease of cells viability | |
| CNT | 1–0.3 mg/Kg body weight | Blocks potassium channels. The suppressed and inhibited IK and potassium channels lead to increased heart rate [ | Microvascular Endothelial Cells | Dose- and time-dependent increasing DNA damage [ | |
| QD | - | - | Human hepatocellular carcinoma, HepG2 cells | Mitochondria-dependent cellular apoptosis associated with ROS [ | |
| Dermal | AgNP | 50 and 100 μg/mL, (24 h) | Mitochondria-dependent cellular apoptosis related to ROS at a concentration of ≥ 50 μg/mL [ | A431 (human skin carcinoma) | No evidence for Cellular damage up to a concentration of 6.25 g/mL. Morphological changes at concentrations between 6.25 and 50 g/mL with concomitant rise in GSH, SOD and lipid peroxidation. |
| TiO2 | 15 μg/cm2, (24 h) | Cytotoxicity was detected to be apoptosis [ | HaCaT (keratinocyte cell line), human dermal fibroblasts, human immortalized sebaceous gland cell line (SZ95) | Cytotoxicity was observed to be affecting cellular functions such as cell proliferation, differentiation and mobility resulting in apoptosis [ | |
| Fe3O4 | 65 nm | - | Skin tumor cells | Increases ROS, deceasing cancer cells [ | |
| CNT | 10 μg/mL, (72 h) | NPs increased relatively IL8 and ROS factors in animal [ | Human Dermal Fibroblast Cells | Mitochondria-dependent cellular apoptosis associated with decrease cell viability [ | |
| QD | 4.6 nm core/shell diameter QD for 8 h and 24 h | Increased IL-1b, IL-6, and IL-8 [ | Human epidermal keratinocytes (HEKs) | Increased IL-1β, IL-6, IL-8, and TNF-α factors [ | |
| Liver | AgNPs | 10, 50, 100, 150, 200, 400 ppm for 24 h | - | Primary mouse fibroblasts, primary hepatocytes | Production of mediators of oxidative-stress. increase GSH [ |
| CdSe | 62.5–1000 µg/mL, (1–8 h) | - | Primary rat hepatocytes | Evidence for cellular damage up to a concentration of 62.5 µg/mL with concomitant rise in GSH, SOD and lipid peroxidation [ | |
| ZnO NPs | 100, 300 and 600 mg/Kg, (7 days) | - | Human hepatocyte (L02) | Mitochondria-dependent cellular apoptosis associated with ROS, reduction of SOD, depletion of GSH, and oxidative DNA damage [ | |
| Al2O3 | 235,245 ppm | Blood cell and melanoma macrophage accumulation, hepatocyte necrosis, vaculation and portal vein alteration [ | - | - | |
| TiO2 | 5, 10, 50, 100 or 150 mg/Kg, (daily for 14 days) | NPs increased relatively IL-8 and ROS factors in animal [ | Rat liver derived cell line (BRL 3A) | Mitochondria-dependent cellular apoptosis associated with ROS, reduction of SOD, depletion of GSH, and oxidative DNA damage [ | |
| CNT | ~25 μg/cm2 | NPs increased relatively apoptosis factor in animal [ | Human hepatoblastoma C3A cell line | Mitochondria-dependent cellular apoptosis associated with ROS, IL8, reduction of SOD, depletion of GSH, and oxidative DNA damage [ | |
| QDs | 1000 µg/mL, (24 h) | NPs increased relatively ROS in liver [ | Primary rat hepatocytes | Cytotoxicity was thought to be due to the release of free cadmium ions [ | |
| Kidney | AuNPs | 5, 10,100 ppm, (via IP injection for 7 successive days) | Increase levels of CREA, UREA, total bilirubin ALP in rats’ blood serum were examined to show a degree of kidney functionality [ | Embryonic kidney cells (HEK293). | Toxicity was dose dependent. In a dose of 44 mg/mL for 4 h, toxicity was observed on DNA/transferrin [ |
| ZnO NPs | 100, 300 and 1000 mg/Kg in 2 weeks | Significant increase in serum creatinine and blood urea nitrogen, decrease in hemoglobin, haematocrit and mean corpuscular hemoglobin concentration [ | Human embryonic kidney (HEK293) cells | Lead to cellular morphological modifications, mitochondrial dysfunction, and cause reduction of SOD, depletion of GSH, and oxidative DNA damage [ | |
| CuO NPs | A dose of 10 mg/Kg three times a week up to 19 injections | Toxicity showed with DNA fragmentation [ | Embryonic kidney cells (HEK293) | Increased ROS, decreased cell viability [ | |
| TiO2 | 1, 10, 100 µg/mL | Embryonic kidney cells | - | DNA damage and genomic toxicity [ | |
| CNT | 4 mg/Kg, (7 days) | Increase level of IL-8, LDH and lipid peroxidation in serum [ | Embryonic kidney cells (HEK293) | Decreased cell viability, increase cell membrane damage, LDH release, reduced glutathione (GSH), interleukin-8 (IL-8), lipid peroxidation [ | |
| QD | 1.5 µmol/Kg, (1, 7, 14, and 28 days) | - | Embryonic kidney cells (HEK293) | Time-dependent decrease of mitochondrial transmembrane potential, up regulate Bcl-2 expression, alleviated apoptosis [ | |
| Spleen | AgNPs | 30, 300 and 1000 mg/Kg doses of AgNPs (60 nm), 28 days of oral administration | Ag induces the permeability of cell membrane to potassium and sodium and interrupts the activity of Na-K-ATPase and mitochondria. Inhibition of NF-kB activity, a decrease in expression bcl-2, increase in caspase-3 expression [ | - | - |
| Fe2O3 | 0.1, 0.5 and 1.0 mg/L (9.2 × 10−4, 4.6 × 10−3 and 9.2 × 10−3 mM) aqueous suspensions for 60 days | Accumulated in the spleen organ and induce acute toxicity [ | - | - | |
| CNT | 1.5 mL; 2 mg multi-walled (MW) CNT per body weight (bw), (1, 6, 24, 48 and 144 h) | After i.p. administration, MWCNT translocate progressively in the spleen, with a peak of concentration after 48 h, and determine lymphoid hyperplasia and an increase in the number of cells which undergo apoptosis, in parallel with the enhancement of the mitosis in the white pulp and with transient alterations of oxidative stress and inflammation [ | - | - | |
| QD | 6000 | Distribution in different body organs and aggregation in spleen [ | - | - | |
| Stomach | AgNPs | 28-day repeated oral dose of AgNPs of 60 nm, 2.6 mg Ag/Kg b.w./day | Aggregation in stomach tissues [ | - | - |
| Au NPs | - | - | Gastrointestinal cancer cells | Removing tumor cells from healthy cells [ | |
| CdSe | 0.84 × 105 µm | - | Human colon carcinoma cell line | Removing tumor cells from healthy cells [ | |
| TiO2 NPs | 1012 particles/person per day in 2 weeks | Aggregation in stomach tissues [ | - | - | |
| ZnO NPs | 5, 50, 300, 1000 and 2000 mg/Kg b.w | Aggregation in stomach tissues [ | - | - | |
| CNT | <5 µm, 10–20 µm, (7 days) | Inflammation [ | - | - | |
| QD | 2 to 200 nmol/mL, (24 h) | NPs increased relativel ROS factors in animal [ | - | - | |
| Pancreas | Ag NPs | AgNPs (100 μg/mL), (24 h) | NPs increased relatively ROS factors in animal [ | Pancreas cancer BxPC-3 Cells | Inhibition of NF-kB activity, a decrease in bcl-2, and an increase in caspase-3 and survivin expression [ |
| AuNPs | 50 nm, 2.5 mg/Kg, Male Wistar diabetic with autism spectrum disorder pups, i.p. 7 day | NPs increased relatively ROS factors in animal [ | - | - | |
| cobalt ferrite NPs | - | - | human pancreatic cancer cells | Accumulation in cells increasing apoptosis [ | |
| ZnO NPs | 0, 500, 1000, and 2000 mg/Kg/day for 14 days. | Decreased body weight, feed consumption, alterations in blood factors (HB, HCT, MCV, MCH, MCHC, and LYM) and increase in blood cells (WBCs and NEUs), and histopathological alterations in the pancreas [ | - | - | |
| TiO2 | 42 days | - | Pancreatic cancer cells (PANC-1) | Tumor growth inhibition and induce cell toxicity [ | |
| CNT | 5, 10 and 50 μg/mL | - | Pancreatic cancer cells (PANC-1) | Hyperthermia; necrosis of malignant cells [ | |
| QD | 0.2 mL, (7 h) | NPs increased relatively ROS factors in animal organ [ | - | - | |
| Ear | AgNPs | 4000 μg/mL AgNPs induced | Hearing loss with partial recovery within 7 days and increasing ROS in animal organ [ | BALB/c 3T3 cell line | Impairment of the mitochondrial function [ |
| SPION | 150 μL of 15 mg/mL, (1–4 h, 4 and 7 days) | Uptake into the CNS parenchyma [ | - | - | |
| CNT | 150 μL of 15 mg/mL, (1, 2, 4 h, 4 and 7 days | Accumulation in CNS parenchyma. No pathological alterations were observed [ | - | - | |
| QD | 1 mg/mL or 4.5 mg/mL), (24 h) | Limb abnormalities, body wall defects, neural tube defects [ | - | - | |
| Eye | AuNPs | 2, 20 and 200 nm, 72 h | NPs increased relatively ROS factors in animal [ | Human corneal cells | Increasing apoptosis and aberrant expression factor pigmentation, development (pax6a, pax6b, otx2, and rx1) and pigmentation (sox10) [ |
| Iron oxide | 2, 20 and 200 nm, (72 h) | NPs increased relatively ROS factors in animal [ | - | - | |
| Silica NPs | 50, 100 and 150 nm, (48 h) | NPs increased relatively ROS in cell [ | - | - | |
| CNT | Up to 750 nm every week for 9 weeks | Eye-irritation, retinal degeneration [ | - | - | |
| QD | 17 weeks of age, in the range of 2.7–3.6 Kg in body weight | Eye-irritation, retinal degeneration [ | - | - |